The future of hemostasis management

Pediatric Blood and Cancer

Volumn 60, Issue SUPPL.1, 2013, Pages

  Lillicrap, David ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

Blood, gene therapy; Hemophilia; Innovation; Protein engineering

Indexed keywords

BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; VON WILLEBRAND FACTOR;

ADAPTIVE IMMUNITY; BLEEDING DISORDER; COMPLEX FORMATION; DISEASE MANAGEMENT; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG HALF LIFE; GENE REPLACEMENT THERAPY; HEMOPHILIA A; HEMOPHILIA B; HEMOSTASIS; HUMAN; IMMUNOGENICITY; INNATE IMMUNITY; LONG TERM CARE; PRIORITY JOURNAL; PROTEIN MODIFICATION; PROTEIN SYNTHESIS; REVIEW; SYNTHESIS;

BLOOD COAGULATION DISORDERS; FACTOR IX; FACTOR VIII; GENETIC THERAPY; HEMORRHAGE; HEMOSTASIS; HEMOSTATICS; HUMANS; PROTEIN ENGINEERING;

EID: 84869212713     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24334     Document Type: Review

References (21)

1. Davie EW. A brief historical review of the waterfall/cascade of blood coagulation. J Biol Chem 2003; 278: 50819-50832.
2. Davidson CJ, Tuddenham EG, McVey JH. 450 Million years of hemostasis. J Thromb Haemost 2003; 1: 1487-1494.
3. Nilsson IM, Berntorp E, Lofqvist T, et al. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992; 232: 25-32.
4. Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535-544.
5. Feldman BM, Pai M, Rivard GE, et al. Tailored prophylaxis in severe hemophilia A: Interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study. J Thromb Haemost 2006; 4: 1228-1236.
6. van DK, Fischer K, van der Bom JG, et al. Can long-term prophylaxis for severe haemophilia be stopped in adulthood? Results from Denmark and the Netherlands. Br J Haematol 2005; 130: 107-112.
7. Astermark J. Basic aspects of inhibitors to factors VIII and IX and the influence of non-genetic risk factors. Haemophilia 2006; 12: 8-14.
8. Lillicrap D. The improved factor concentrate. Hamostaseologie 2009; 29: 71-73.
9. Powell JS. Liposomal approach towards the development of a longer-acting factor VIII. Haemophilia 2007; 13: 23-28.
10. Negrier C, Knobe K, Tiede A, et al. Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: A first human dose trial in patients with hemophilia B. Blood 2011 [Epub ahead of print].
11. Mei B, Pan C, Jiang H, et al. Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment. Blood 2010; 116: 270-279.
12. Peters RT, Low SC, Kamphaus GD, et al. Prolonged activity of factor IX as a monomeric Fc fusion protein. Blood 2010; 115: 2057-2064.
13. Moss J, Rosholm A, Lauren A. Safety and pharmacokinetics of a glycoPEGylated recombinant activated factor VII derivative: A randomized first human dose trial in healthy subjects. J Thromb Haemost 2011; 9: 1368-1374.
14. Gray LD, Hussey MA, Larson BM, et al. Recombinant factor VIIa analog NN1731 (V158D/E296V/M298Q-FVIIa) enhances fibrin formation, structure and stability in lipidated hemophilic plasma. Thromb Res 2011; 128: 570-576.
15. Niemeyer GP, Herzog RW, Mount J, et al. Long term correction of inhibitor prone hemophilia B dogs treated with liver-directed AAV2 mediated factor IX gene therapy. Blood 2009; 113: 797-806.
16. Jiang H, Lillicrap D, Patarroyo-White S, et al. Multiyear therapeutic benefit of AAV serotypes 2, 6 and 8 delivering factor VIII to hemophilia A mice and dogs. Blood 2006; 108: 107-115.
17. Margaritis P, High KA. Gene therapy in haemophilia-going for cure? Haemophilia 2010; 16: 24-28.
18. Nathwani A, Tuddenham E, Rangarajan S, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 2011; 365: 2357-2365.
19. Lloyd JM, Wight J, Paisley S, et al. Control of bleeding in patients with haemophilia A with inhibitors: A systematic review. Haemophilia 2003; 9: 464-520.
20. Waters EK, Genga RM, Schwartz MC, et al. Aptamer ARC19499 mediates a procoagulant hemostatic effect by inhibiting tissue factor pathway inhibitor. Blood 2011; 117: 5514-5522.
21. Prasad S, Lillicrap D, Labelle A, et al. Efficacy and safety of a new-class hemostatic drug candidate, AV513, in dogs with hemophilia A. Blood 2008; 111: 672-679.